secwatch / observer
8-K filed December 19, 2025, 6:59 PM ET ticker PROF CIK 0001628808
other material confidence high sentiment neutral materiality 0.70

Profound Medical prices $36M registered direct offering and up to $4M private placement at $7.00/share

Profound Medical Corp.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.88

Profound Medical Corp. entered into Placement Agent Agreement with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC valued at cash fee of 5.0% of gross proceeds from the sale of Shares plus reimbursement of documented out-of-p (effective 2025-12-19).

Action
entry
Agreement
underwriting
Counterparty
Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC
Value
cash fee of 5.0% of gross proceeds from the sale of Shares plus reimbursement of documented out-of-p
Effective
2025-12-19
Exact text from the filing
On December 19, 2025, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with Konik Capital Partners, LLC, a division of T.R. Winston and Company, LLC (“Konik Capital Partners”) pursuant to which the Company engaged Konik Capital Partners as the placement agent (the “Placement Agent”) in connection with the Offering.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Profound Medical Corp. entered into Securities Purchase Agreement with certain investors (the Purchasers) valued at aggregate of 5,142,870 common shares at $7.00 per share for aggregate gross proceeds of $36 million (effective 2025-12-19).

Action
entry
Agreement
equity purchase
Counterparty
certain investors (the Purchasers)
Value
aggregate of 5,142,870 common shares at $7.00 per share for aggregate gross proceeds of $36 million
Effective
2025-12-19
Exact text from the filing
On December 19, 2025, Profound Medical Corp. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (collectively, the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (the “Offering”) an aggregate of 5,142,870 shares (the “Shares”) of the Company’s common shares (the “Common Shares”), at a price of $7.00 per share, for aggregate gross proceeds to the Company of $36 million before deducting the placement agent’s fees and related offering expenses.
View on SEC.gov

Browse all material agreements →

Profound Medical Corp. filing history →

Source: SEC EDGAR
accession 0001104659-25-123211
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.